197 related articles for article (PubMed ID: 22438252)
1. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.
Porcu M; Kleppe M; Gianfelici V; Geerdens E; De Keersmaecker K; Tartaglia M; Foà R; Soulier J; Cauwelier B; Uyttebroeck A; Macintyre E; Vandenberghe P; Asnafi V; Cools J
Blood; 2012 May; 119(19):4476-9. PubMed ID: 22438252
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
Sharma ND; Nickl CK; Kang H; Ornatowski W; Brown R; Ness SA; Loh ML; Mullighan CG; Winter SS; Hunger SP; Cannon JL; Matlawska-Wasowska K
Cancer Sci; 2019 Jun; 110(6):1931-1946. PubMed ID: 30974024
[TBL] [Abstract][Full Text] [Related]
3. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
Girardi T; Vereecke S; Sulima SO; Khan Y; Fancello L; Briggs JW; Schwab C; de Beeck JO; Verbeeck J; Royaert J; Geerdens E; Vicente C; Bornschein S; Harrison CJ; Meijerink JP; Cools J; Dinman JD; Kampen KR; De Keersmaecker K
Leukemia; 2018 Mar; 32(3):809-819. PubMed ID: 28744013
[TBL] [Abstract][Full Text] [Related]
4. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
5. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Kleppe M; Soulier J; Asnafi V; Mentens N; Hornakova T; Knoops L; Constantinescu S; Sigaux F; Meijerink JP; Vandenberghe P; Tartaglia M; Foa R; Macintyre E; Haferlach T; Cools J
Blood; 2011 Jun; 117(26):7090-8. PubMed ID: 21551237
[TBL] [Abstract][Full Text] [Related]
6. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
7. CD45 antigen negativity in T-lineage ALL correlates with PTPRC mutation and sensitivity to a selective JAK inhibitor.
Raponi S; Gianfelici V; Chiaretti S; Peragine N; Brugnoletti F; De Propris MS; Marinelli M; Hulselmans G; Aerts S; Geerdens E; Cools J; Foà R; Guarini A
Br J Haematol; 2015 Dec; 171(5):884-7. PubMed ID: 25854815
[No Abstract] [Full Text] [Related]
8. Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.
Lo MC; Peterson LF; Yan M; Cong X; Jin F; Shia WJ; Matsuura S; Ahn EY; Komeno Y; Ly M; Ommen HB; Chen IM; Hokland P; Willman CL; Ren B; Zhang DE
Blood; 2012 Aug; 120(7):1473-84. PubMed ID: 22740448
[TBL] [Abstract][Full Text] [Related]
9. Multiomics to investigate the mechanisms contributing to repression of PTPRC and SOCS2 in pediatric T-ALL: Focus on miR-363-3p and promoter methylation.
Drobna-Śledzińska M; Maćkowska-Maślak N; Jaksik R; Kosmalska M; Szarzyńska B; Lejman M; Sędek Ł; Szczepański T; Taghon T; Van Vlierberghe P; Witt M; Dawidowska M
Genes Chromosomes Cancer; 2022 Dec; 61(12):720-733. PubMed ID: 35778917
[TBL] [Abstract][Full Text] [Related]
10. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
11. Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma.
Kleppe M; Tousseyn T; Geissinger E; Kalender Atak Z; Aerts S; Rosenwald A; Wlodarska I; Cools J
Haematologica; 2011 Nov; 96(11):1723-7. PubMed ID: 21791476
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract][Full Text] [Related]
13. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
14. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.
Vicente C; Schwab C; Broux M; Geerdens E; Degryse S; Demeyer S; Lahortiga I; Elliott A; Chilton L; La Starza R; Mecucci C; Vandenberghe P; Goulden N; Vora A; Moorman AV; Soulier J; Harrison CJ; Clappier E; Cools J
Haematologica; 2015 Oct; 100(10):1301-10. PubMed ID: 26206799
[TBL] [Abstract][Full Text] [Related]
15. New insights into the transmembrane protein tyrosine phosphatase CD45.
Sasaki T; Sasaki-Irie J; Penninger JM
Int J Biochem Cell Biol; 2001 Nov; 33(11):1041-6. PubMed ID: 11551820
[TBL] [Abstract][Full Text] [Related]
16. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
17. Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.
Podshivalova K; Wang EA; Hart T; Salomon DR
Leuk Res; 2018 Nov; 74():1-9. PubMed ID: 30269036
[TBL] [Abstract][Full Text] [Related]
18. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
Treanor LM; Zhou S; Janke L; Churchman ML; Ma Z; Lu T; Chen SC; Mullighan CG; Sorrentino BP
J Exp Med; 2014 Apr; 211(4):701-13. PubMed ID: 24687960
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
